Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials
|
|
- Victor Chapman
- 5 years ago
- Views:
Transcription
1 Paper PO05 Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Ping Liu ABSTRACT In any phase of clinical trials, dates are very critical throughout the entire trial. However, since incomplete dates are inevitable during the clinical data collection process, and missing dates will cause numerous problems to the study, there is a need to investigate the method of handling the missing dates. We do have different imputation methods for partial missing dates in different companies or different therapeutic areas, but we don t have a systematic method for varied missing situations. Developing a systematic inductive method for imputing the missing dates in varied situations is the topic of this paper. The paper will categorize missing dates into three status (whole date missing, month and day missing, only day missing), and utilize a systematic inductive method to impute the partial missing dates. A simple SAS macro will be included. This method serves as a hint for handling missing dates in different situations and different time points. INTRODUCTION Working in different companies or different therapeutic areas, we often encounter the situation in which quite an amount of time is being spent to discuss rules and develop imputation algorithms when incomplete dates occur in different studies. Sometimes we don t even recognize that we have encountered and discussed the same situations before because these missing dates situations are handled on an ad-hoc basis rather than being summarized and processed in a systematic way. Thus, it doesn t matter whether the missing dates are the start date or end date of drug compliance, medication history, concomitant medication, AE; whether the missing dates are the study completion date, discontinued date or death date; whether the missing dates are the sample dates in LAB, ECG or Vital Signs. We can summarize the missing dates into three categories: (1) the whole date is missing, (2) both of day and month are missing and (3) only day is missing. Furthermore, the imputation algorithms are developed based on a target date. This paper will discuss all of the three missing categories, but mostly focus on categories (2) and (3). Section 1 will describe how to categorize the clinical trial missing dates and how to handle the whole missing dates. Section 2 will categorize the partial missing dates and define the target date and variables names to utilize a systematic inductive method for imputing partial missing dates. Section 3 will provide a SAS macro implementing the method described in Section 2.
2 1. WHOLE DATE MISSING In clinical trials, dates can be grouped according to their related procedures, date related to the medical intervention, date related to an unplanned event and date related to a planned clinical evaluation. No matter what type of date it is, complete date information should be collected whenever possible. However, due to numerous reasons, missing dates are very often seen in clinical trials at different stages. Missing dates may occur because of errors by patients, investigators or data monitors, or during the data transfer. No matter what the cause, missing dates can be categorized into (1) due to human error and (2) due to unknown reasons. Some human errors can be fixed by queries during the data cleaning process, but some human errors can not be fixed because of numerous reasons (e.g., tight timeline, clinical procedure orders, etc.). Those unfixed errors may cause problems in the analysis of the study. How to handle missing dates due to unfixed errors is the topic of this paper. Generally, the imputation algorithms depend on the type of events and the time when those missing dates occurred. Different cases may adopt different imputation algorithms, thus adopting appropriate imputations algorithm becomes critical. In some cases, the traditional last observation carried forward (LOCF) method can be adopted while in some other cases the imputation algorithm needs to be based on the specific situation. The imputation algorithms also need to be dependent on the way the data is collected. The following summarizes the type of date, according to the relationship to the clinical procedure, and some current practices of imputation when the whole date is missing. 1.1 Date of Intervention Date related to medical intervention such as investigational treatment, concurrent medical treatment or surgical procedures. In most cases, these dates are rarely missing, however, if the start date of the intervention is missing, an ad-hoc date is used to impute the missing date. If the end date of the intervention is missing, the date of the last visit to the clinical site is used to impute the missing date. If the interim date of intervention is missing, the corresponding interim visit date is used to impute the missing date. 1.2 Date of Events Date of occurrence or incidence which is independent of planned clinical evaluations. The examples of these dates are AE, Medical History or Concomitant Medications. It is common to see missing dates for these events, especially the month and day missing. The way to handle the missing whole date depends on the specific situation, where the LOCF is often used or the study cut point date is used to impute the missing end date. The interim study date (e.g. study visit date, lab date) sometimes is used to impute the missing interim date. 1.3 Date of Findings Date on which the results from planned evaluations are observed. The examples of these dates are physical exams, test results (ECG, LAB, Vital Signs, other tests), and questionnaires. It is rare that the planned evaluation date is missing. If it is missing, then it is common practice to use the closest visit date to impute the missing date.
3 2. PARTIAL DATE MISSING 2.1 Method and Definition In Section 1 we discussed the situations where the whole date (year, month and day) is missing. In this section, we will discuss the situations where only partial date (month or day) is missing. It is often seen in clinical trials that the date of some past event is often recalled by year or best by year and month. There are numerous methods available for handling the partial missing date. However, these methods are adopted on an ad-hoc basis and hence there is lack of consistency among these methods. A systematic way of handling the partial missing date is developed. The basic concept of this method is to impute the partial missing date based on a target date rather than using an ad-hoc date. The target date is defined as the reference date for the study analysis. It will be driving the points of the study analysis. We can define the treatment randomization date as the target date to impute the treatment start date. We can define the treatment start date as the target date to impute the AE partial missing dates. We can define the visit date as the target date to impute a partial missing date for planned evaluations dates etc. After target date is defined, we can sum up the imputation dates in three ways: 1. The imputing event date could only happen before the target date 2. The imputing event date could only happen after the target date 3. The imputing event date could happen either before or after the target date. We simplify all partial missing date imputations by the target date. How to distinguish it will be discuss in the following sections. 2.2 Define the Dates Variables Before we discuss the imputation methods, let us setup the date variables as follows: Variable name Datevar Yvar Mvar Dvar Trtstd Trty Trtm Trtd Variable descript event date event year event month event day target date target year target month target day 2.3 The Event Dates Occurred Before the Target Date For example of datasets: Randomization Datasets Medication History Concomitant History (sometimes) prior to start of study date Therapeutic Disease Medication prior to start of study date Any Medication Information prior to start of study date First study date is defined as the target date for those kinds of imputing partial missing date. For this type of partial missing date imputation proposal is as follows:
4 YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. MVAR^=TRTM MVAR=TRTM TRTSTD-1 15/MVAR/YVAR min(15/mvar/yvar,trtstd-1) 2.4 The Event Date Occurred After the Target Date For example of datasets: Adverse Events after treatment study date Study completion information after treatment study date For this type of dataset, partial missing date imputation proposal is as follows: YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. MVAR^=TRTM MVAR=TRTM TRTSTD+1 15/MVAR/YVAR max(15/mvar/yvar,trtstd+1) 2.5 The Event Date Occurred Crossing the Target Date For example of datasets: Vital signs A_VSN ECG Laboratory A_LRS Bone Markers Quality of Life YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. 01/JULY/YVAR 2.6 Summarized above three types of date sets imputation as follows: YVAR^=. YVAR^=TRTY MVAR=. 01/JULY/YVAR YVAR=TRTY MVAR=. 1. TRTSTD-1 if TRTSTD<01/JULY/YVAR 01/JULY/YVAR otherwise 2. TRTSTD+1 if TRTSTD>01/JULY/YVAR
5 01/JULY/YVAR otherwise 3. 01/JULY/YVAR MVAR^=. MVAR^=TRTM 15/MVAR/YVAR MVAR=TRTM 1.min(15/MVAR/YVAR,TRTSTD-1) 2.max(15/MVAR/YVAR,TRTSTD+1) 3. 15/MVAR/YVAR Notes: 1--The event dates in the dataset are happen before the target date. 2-- The event dates in the dataset are happen after the target date. 3-- The event dates in the dataset are happen crossing the target date In the summarized partial missing date imputation above, we can change imputation numbers of 01/JULY, 15, TRTSTD-1 and TRTSTD+1 to apply in terms of different purpose of the study analysis. 3. MACRO FOR IMPUTING PARTIAL MISSING DATES Based on the methods discussed in Section 2, a SAS macro is provided to implement these methods. The macro is simple, can be understood easily, and is also flexible. You may need to make a simple modification based on your target date to satisfy the macro s requirement. The program creating a dummy dataset is provided in Section 3.2. You will get tips for creating a dummy dataset and for how to manipulate dates. Two examples will show you how to handle and modify different date formats to apply the macro. 3.1 Macro for Partial Missing Dates ******************************************************** * Macro for impute partial missing dates * this macro can only be used inside data steps * all the parameter variables are assumed numeric except trtdt * macro variables definition: * datvar: imputed date * dvar: need to be imputed day * mvar: need to be imputed month * yvar: need to be imputed year * imflag: flag to be used for distinguishing type of imputing date * trtsdt: target variable * trty: year of the target date * trtm: month of the target date * trtd: day of the target date ***************************************************; %macro missdat(datvar=,dvar=, mvar=, yvar=,imflag=,trtsdt=, trty=,trtm=,trtd=); if &datvar eq. and &yvar ne. then do; if &mvar eq. then do; if &imflag=1 and &yvar=&trty and &trtsdt<input(( 01jul &yvar)d,date9.) then do; &mvar=&trtm; &dvar=&trtd.-1; end; else if &imflag=2 and &yvar=&trty and &trtsdt>input(( 01jul &yvar)d,date9.) then do; &mvar=&trtm; &dvar=&trtd.+1; end; else do; &mvar = 7; &dvar = 15; end;
6 end; else if &dvar eq. then do; if &imflag=1 and &trtd<&dvar and &yvar=&trty and &mvar=&trtm then &dvar=min(15,&trtd.-1); else if &imflag=2 and &trtd>&dvar and &yvar=&trty and &mvar=&trtm then &dvar=max(15,&trtd.+1); else &dvar = 15; end; datvar = mdy(&mvar,&dvar,&yvar); end; %mend missdat; 3.2 Dummy Datasets ************************************* * create a dummy datasets **************************************; data sample(keep=pat visit fdosdt mon day yr sdtc); retain pat visit fdosdt sampdtn sampdtc mon day yr sdtc; format fdosdt sampdtn date9.; do pat=1 to 5; fdosdt='15apr2003'd + pat*30; do visit=1 to 3; sampdtn='11apr2003'd+visit*2 +pat*30 ; sampdtc=put(sampdtn,date9.); if visit=2 and pat in(2,4) then do; yr=year(sampdtn); mon=.; day=.; end; else if visit=2 and pat in(3,5) then do; yr=year(sampdtn); mon=month(sampdtn); day=.; end; else if visit=3 and pat in(2,5) then do; yr=year(sampdtn); mon=.; day=.; end; else if visit=3 and pat in(1,2) then do; yr=year(sampdtn); mon=month(sampdtn); day=.;end; else do;yr=year(sampdtn);mon=month(sampdtn);day=day(sampdtn);end; if mon in(0,.) then do; sdtc=right(' ' put(yr,z4.)); end; else if day in(0,.) then do; sdtc=right(' ' substr(sampdtc,3,3) put(yr,z4.)); end; else sdtc=sampdtc; output; end; end; run; proc print; run; DATASET SAMPLE Obs pat visit fdosdt mon day yr sdtc MAY MAY MAY MAY MAY MAY JUN JUN JUN JUN
7 JUL JUL JUL JUL JUL JUL AUG AUG AUG AUG AUG SEP SEP SEP SEP SEP Examples ******************************************************************** Example 1. Each date already have separated year and month and day variables. *************************************************************************************; data sample1; set sample; trty=year(fdosdt); trtm=month(fdosdt); trtd=day(fdosdt); %missdat(datvar=impdt,dvar=day, mvar=mon, yvar=yr, imflag=1,trtsdt=fdosdt, trty=trty,trtm=trtm,trtd=trtd); run; ******************************************************************** Example 2. Sample date and target date do not have numerical year, month and day variables. *************************************************************************************; data sample2; set sample; format impdt date9.; **get year month and day variables from sample date; dday=input(substr(sdtc,1,2),best.); **month=letter for conversion; mon1 = '01' substr(sdtc,3,3) substr(sdtc,6); mon = month(input(mon1,?? date9.)); yr =input(substr(sdtc,6 ),best.); **get year month and day variables from target date; dayt=day(fdosdt); mont= month(fdosdt); yrt =year(fdosdt); %missdat(datvar=impdt2,dvar=dday, mvar=mon, yvar=yr,imflag=1,trtsdt=fdosdt,trty=yrt,trtm=mont,trtd=dayt); drop dday mon1 mon yr vis1d dayt mont yrt; run;
8 CONCLUSION Based on pharmaceutical industry experience, this presentation summarizes the simple ways to impute the whole missing date and develops a systematic method for imputing partial missing date. This presentation serves as a hint for the basic imputation references for missing dates as well as tips for using SAS date and string functions from the macro and samples, and tips for how to create a dummy dataset. ACKNOWLEDGEMENTS The author would like to thank Ms. Margaret McAlary, my supervisor, for her encouragement and comments during the development of this presentation. CONTACT INFORMATION Ping Liu Biostatistics & Statistical Reporting Novartis Pharmaceuticals Corporation One Health Plaza East Hanover, NJ ping.liu@novartis.com
A SAS sy Study of ediary Data
A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)
More informationImplementing Worst Rank Imputation Using SAS
Paper SP12 Implementing Worst Rank Imputation Using SAS Qian Wang, Merck Sharp & Dohme (Europe), Inc., Brussels, Belgium Eric Qi, Merck & Company, Inc., Upper Gwynedd, PA ABSTRACT Classic designs of randomized
More informationWhat makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012
What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 Disclaimer The opinions expressed in this presentation and on the following slides are solely
More informationPROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables
PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep
More informationPaper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ
Paper number: CC02 MACRO %NEWFLOW JIAN HUA (DANIEL) HUANG, FOREST LABORATORIES INC, NJ ABSTRACT: If you use SAS Proc Report frequently, you will be familiar with the flow option. The flow option wraps
More informationPharmaceutical Applications
Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationStrategies for handling missing data in randomised trials
Strategies for handling missing data in randomised trials NIHR statistical meeting London, 13th February 2012 Ian White MRC Biostatistics Unit, Cambridge, UK Plan 1. Why do missing data matter? 2. Popular
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
2 Synopsis Title of study: An Investigator-blind, Controlled Study to Assess the Efficacy of Five Distinct Combinations of in Different Concentrations Compared to Placebo and to Two Active Controls in
More informationA SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial
A SAS Macro to Present a Summary Table of the Number of Patients Having Experienced Adverse Events in a Clinical Trial Christoph Gerlinger * and Ursula Franke ** * Laboratoires Fournier S.C.A. and ** biodat
More informationProgrammatic Challenges of Dose Tapering Using SAS
ABSTRACT: Paper 2036-2014 Programmatic Challenges of Dose Tapering Using SAS Iuliana Barbalau, Santen Inc., Emeryville, CA Chen Shi, Santen Inc., Emeryville, CA Yang Yang, Santen Inc., Emeryville, CA In
More informationDescription and instructions for the use of SAS macros for the selfcontrolled
Description and instructions for the use of SAS macros for the selfcontrolled case series analyses Two SAS macros have been developed to analyse self-controlled case series (SCCS) data. The macro %SCCSDTA
More informationCollapsing Longitudinal Data Across Related Events and Imputing Endpoints
Collapsing Longitudinal Data Across Related Events and Imputing Endpoints James Joseph, INC Research, King of Prussia, PA INTRODUCTION When attempting to answer a research question, the best study design
More informationBEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS
BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior
More informationImproved Transparency in Key Operational Decisions in Real World Evidence
PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International
More informationInsomnia: What Happens When You Can't Sleep By Donnee Patrese
Insomnia: What Happens When You Can't Sleep By Donnee Patrese If you are looking for a ebook Insomnia: What happens when you can't sleep by Donnee Patrese in pdf form, then you have come on to the right
More informationA SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method
Paper SP01 A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Don (Dongguang) Li, NCIC-CTG, Queen s University, Kingston, ON, Canada ABSTRACT The Health-Related Quality of Life
More informationABSTRACT INTRODUCTION
Adaptive Randomization: Institutional Balancing Using SAS Macro Rita Tsang, Aptiv Solutions, Southborough, Massachusetts Katherine Kacena, Aptiv Solutions, Southborough, Massachusetts ABSTRACT Adaptive
More informationMethods for Computing Missing Item Response in Psychometric Scale Construction
American Journal of Biostatistics Original Research Paper Methods for Computing Missing Item Response in Psychometric Scale Construction Ohidul Islam Siddiqui Institute of Statistical Research and Training
More informationMaintenance of weight loss and behaviour. dietary intervention: 1 year follow up
Institute of Psychological Sciences FACULTY OF MEDICINE AND HEALTH Maintenance of weight loss and behaviour change Dropouts following and a 12 Missing week healthy Data eating dietary intervention: 1 year
More informationAE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd.
PharmaSUG 2016 - Paper IB11 AE: An Essential Part of Safety Summary Table Creation. Rucha Landge, Inventiv International Pharma Services Pvt. Ltd., Pune, India ABSTRACT Adverse event (AE) summary tables
More informationGraph Display of Patient Profile Using SAS
PharmaSUG 2018 - Paper DV-17 Graph Display of Patient Profile Using SAS Yanwei Han, Seqirus USA Inc., Cambridge, MA Hongyu Liu, Seqirus USA Inc., Cambridge, MA ABSTRACT We usually create patient profile
More informationCombining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study
PharmaSUG 2018 - Paper RW-02 Combining Electronic Diary Seizure Data with Visit-Based Seizure Data in the MONEAD Study Julia Skinner and Ryan May, Emmes Corporation ABSTRACT Electronic diary (ediary) mobile
More informationStatistical Analysis Plan (SAP)
Statistical Analysis Plan (SAP) Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax in Ethiopia: a randomized controlled trial Contents
More informationCertificate Courses in Biostatistics
Certificate Courses in Biostatistics Term I : September December 2015 Term II : Term III : January March 2016 April June 2016 Course Code Module Unit Term BIOS5001 Introduction to Biostatistics 3 I BIOS5005
More informationHow the ICH E9 addendum around estimands may impact our clinical trials
Danish Society for Biopharmaceutical Statistics Copenhagen October 26, 2017 How the ICH E9 addendum around estimands may impact our clinical trials Frank Bretz (Novartis) ICH E9(R1) Expert Working Group
More informationADaM Tips for Exposure Summary
ABSTRACT PharmaSUG China 2016 Paper 84 ADaM Tips for Exposure Summary Kriss Harris, SAS Specialists Limited, Hertfordshire, United Kingdom Have you ever created the Analysis Dataset for the Exposure Summary
More informationNote to the interviewer: Before starting the interview, ensure that a signed consent form is on file.
STUDY QUESTIONNAIRE FOR PATIENT TELEPHONE SURVEY Note to the interviewer: Fill out prior to the interview: 1) Participant ID 2) Date of non-invasive treatment / / 3) Interviewer name 4) Date of interview
More informationA SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia
Paper 109 A SAS Macro to Investigate Statistical Power in Meta-analysis Jin Liu, Fan Pan University of South Carolina Columbia ABSTRACT Meta-analysis is a quantitative review method, which synthesizes
More informationMs Masabata Annah Motaung, Agricultural Research Council-Onderstepoort Veterinary Institute
The value of adhering to turnaround times in the Bacteriology and Zoonotic Diseases Laboratories at Onderstepoort. An assessment over 2 years. Ms Masabata Annah Motaung, Agricultural Research Council-Onderstepoort
More informationAn Introduction to Multiple Imputation for Missing Items in Complex Surveys
An Introduction to Multiple Imputation for Missing Items in Complex Surveys October 17, 2014 Joe Schafer Center for Statistical Research and Methodology (CSRM) United States Census Bureau Views expressed
More informationStatistical Analysis Plan FINAL. DexComG4 (DexCom Corporation) CGMMDI GOLD-Study
1.0 Page 1 of 15 FINAL DexComG4 (DexCom Corporation) CGMMDI GOLD-Study monitoring (CGM) in individuals with type 1 diabetes treated 2016-07-07 Approvals Name/Title: Nils-Gunnar Pehrsson / Statistiska Konsultgruppen,
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/573. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex sodium (ABT-711) Individual Study Table Referring to Part of Dossier: Volume: Page: (For National
More informationA journey towards estimand specification in pain: motivation and challenges
Biostatistics Neuroscience Franchise A journey towards estimand specification in pain: motivation and challenges Francesca Callegari, PhD PSI Meeting Reading, UK Sep 27 th, 2017 pdated Slide Quote We shall
More informationEstimands. EFPIA webinar Rob Hemmings, Frank Bretz October 2017
Estimands EFPIA webinar Rob Hemmings, Frank Bretz October 2017 Why estimands? To explain which treatment effect is described to prescribers and other stakeholders. To align objectives with (design and)
More informationBRL /RSD-101C0F/1/CPMS-716. Report Synopsis
Report Synopsis Study Title: A Multicenter, Open-label, Six-Month Extension Study to Assess the Long-Term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive-Compulsive
More informationStepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality
Week 9 Hour 3 Stepwise method Modern Model Selection Methods Quantile-Quantile plot and tests for normality Stat 302 Notes. Week 9, Hour 3, Page 1 / 39 Stepwise Now that we've introduced interactions,
More informationToday s EPDs are not a middle point in evolution. They are one step down from the middle point in evolution. They share elements of desire and
Today s EPDs are not a middle point in evolution. They are one step down from the middle point in evolution. They share elements of desire and fulfilment, but also of pure frustration. In line with tradition,
More informationA Practical Guide to Getting Started with Propensity Scores
Paper 689-2017 A Practical Guide to Getting Started with Propensity Scores Thomas Gant, Keith Crowland Data & Information Management Enhancement (DIME) Kaiser Permanente ABSTRACT This paper gives tools
More informationNCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits
NCC Pediatrics Continuity Clinic Curriculum: Medical Home Module 2 Well Visits Overall Goal: To identify strategies for providing comprehensive care during a well visit. The provision of comprehensive
More informationResearch Compliance and Quality Assurance Program (RCQA): Audit Checklist Subject Specific
Protocol Title / Code: Sponsor: PI Name: Auditor Name: Audit Date(s): Subject #: Key Dates: Date participant was identified: Date of Initial Consent: Date of Optional Consent: Date of Re-consent(s): Date
More informationAUG Expert responses to issues raised by British Gas during the query period for the first draft 2017/18 AUG Statement, 14 March 2017.
AUG Expert responses to issues raised by British Gas during the query period for the first draft 2017/18 AUG Statement, 14 March 2017. Below are the issues raised by British Gas. Following each issue is
More information****************************************************************************
***************************************************************************** **Updated: 2014-AUGUST-15 **Project: Fully automated waist-worn accelerometer algorithm for children s sleep period time separate
More informationMe 9. Time. When It's. for a. By Robert Tannenboum./ Industrial'Relations
W/ When It's for a Time CHANG Ei.. By Robert Tannenboum./ Me 9 j 1*j & I,, A reprint of the Institute of University oftcalifornia Los Angeles 24, California Industrial'Relations INST iutc OF INDUS ;Rl-L
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tasigna) Reference Number: CP.PHAR.76 Effective Date: 09.01.11 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationWhat s New in SUDAAN 11
What s New in SUDAAN 11 Angela Pitts 1, Michael Witt 1, Gayle Bieler 1 1 RTI International, 3040 Cornwallis Rd, RTP, NC 27709 Abstract SUDAAN 11 is due to be released in 2012. SUDAAN is a statistical software
More informationCONSENT FORM. The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith
CONSENT FORM The Full Study Title Should Be Placed Here. Principal Investigator: Dr. John Smith Sub-Investigator: Dr. Jane Smith Queen Elizabeth Hospital Queen Elizabeth Hospital 60 Riverside Drive 60
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationMonitoring Protocol for Clozapine-induced Myocarditis. Copyright 2017, CAMH
1 Monitoring Protocol for Clozapine-induced Myocarditis 1 Agenda Problem Identification / Identification Importance / Importance Baseline Workflow Baseline Workflow Baseline Data Baseline Data Objectives
More informationPart I. Boolean modelling exercises
Part I. Boolean modelling exercises. Glucose repression of Icl in yeast In yeast Saccharomyces cerevisiae, expression of enzyme Icl (isocitrate lyase-, involved in the gluconeogenesis pathway) is important
More informationStatistical Analysis Plan RH01649 Version Document Identifier Effective Date eldo_clinical_doc Reason For Issue
STATISTICAL ANALYSIS PLAN FOR PROTOCOL RH01649 A Study to Assess Efficacy over Placebo and Speed of Onset of Pain Relief of New Panadol Extra as Compared to Ibuprofen in Episodic Tension Headache BIOSTATISTICS
More informationOnline Supplement to A Data-Driven Model of an Appointment-Generated Arrival Process at an Outpatient Clinic
Online Supplement to A Data-Driven Model of an Appointment-Generated Arrival Process at an Outpatient Clinic Song-Hee Kim, Ward Whitt and Won Chul Cha USC Marshall School of Business, Los Angeles, CA 989,
More informationINFORMATION BROCHURE - ALLOCATE
INFORMATION BROCHURE - ALLOCATE AustraLian Ovarian Cancer Assortment Trial Principal Investigator: Prof Michael Quinn, Royal Women s Hospital This Participant Information Sheet and Consent Form is 7 pages
More informationDesigning and Analyzing RCTs. David L. Streiner, Ph.D.
Designing and Analyzing RCTs David L. Streiner, Ph.D. Emeritus Professor, Department of Psychiatry & Behavioural Neurosciences, McMaster University Emeritus Professor, Department of Clinical Epidemiology
More informationPROC SQL. By Becky Leung Alberta Health Services. Calgary SAS User Group Meeting Wednesday, October 08, 2014
PROC SQL By Becky Leung Alberta Health Services Calgary SAS User Group Meeting Wednesday, October 08, 2014 WHAT IS PROC SQL? A Base SAS procedure that combines the functionality of DATA and PROC steps
More informationSingle market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals : regulatory framework and market authorisations Brussels,
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationWill your lungs regenerate after you quit smoking
Will your lungs regenerate after you quit smoking The Borg System is 100 % Will your lungs regenerate after you quit smoking 30-3-2010 After quitting smoking, it is important to help the lungs. After quitting
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationLecture 2. Key Concepts in Clinical Research
Lecture 2 Key Concepts in Clinical Research Outline Key Statistical Concepts Bias and Variability Type I Error and Power Confounding and Interaction Statistical Difference vs Clinical Difference One-sided
More informationEfficacy/pharmacodynamics: 85 Safety: 89
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: Sanofi Drug substance:
More informationHealthcare Research You
DL for Healthcare Goals Healthcare Research You What are high impact problems in healthcare that deep learning can solve? What does research in AI applications to medical imaging look like? How can you
More informationDraft ICH Guidance on Estimands and Sensitivity Analyses: Why and What?
Draft ICH Guidance on Estimands and Sensitivity Analyses: Why and What? Devan V. Mehrotra Merck Research Laboratories Acknowledgement: ICH E9/R1 Expert Working Group Conference on Statistical Issues in
More informationExtract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro
SESUG 2016 Paper CC-160 Extract Information from Large Database Using SAS Array, PROC FREQ, and SAS Macro Lifang Zhang, Department of Biostatistics and Epidemiology, Augusta University ABSTRACT SAS software
More informationHas the UK had a double epidemic?
Has the UK had a double epidemic? Dr Rodney P Jones Healthcare Analysis & Forecasting www.hcaf.biz hcaf_rod@yahoo.co.uk Introduction Outbreaks of a new type of epidemic, possibly due to immune manipulation,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationThank you very much for your guidance on this revision. We look forward to hearing from you.
1 PAINTED BUNTING MANUSCRIPT REVIEW HISTORY REVISION NOTES FROM AUTHORS (ROUND 2) We would like to submit a revision of our manuscript. As you requested, we have run new studies that employ additional
More informationClozapine Clinic Treatment Centre, St Georges Park
Clozapine Clinic Treatment Centre, St Georges Park Patient Information Leaflet Shining a light on the future This leaflet is relevant to the following clinic: St Georges Park Hospital Morpeth Northumberland
More informationCP316 Microprocessor Sysytems and Interfacing Evaluation Results Wilfrid Laurier University
CP316 Microprocessor Sysytems and Interfacing Terry Sturtevant This evaluation for the purpose of evaluating my teaching methods and your impressions of the course. It is anonymous and you can omit any
More informationStudy Center(s): The study was conducted at 39 study sites in Japan.
SYNOPSIS Issue Date: 20 NOVEMBER 2012 Name of Sponsor/Company Janssen Pharmaceutical K. K. Name of Finished Product CONCERTA Name of Active Ingredient(s) Methylphenidate HCl Protocol No.: JNS001-JPN-A01
More informationCincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018
Cincinnati Children s Hospital Medical Center PHO/OVPCA Constipation Initiative Monthly Report February 2018 Aim: Project focus to embed evidence based protocol for the treatment of Constipation in the
More informationPaper DM05 Using Empirical Rules in Quality Control of Clinical Laboratory Data
Paper DM05 Using Empirical Rules in Quality Control of Clinical Laboratory Data ABSTRACT Faustino Daria, Jr. Senior Statistical Programmer Kendle International, Inc. Cincinnati, OH A statistical programmer
More informationMilitary Acute Concussion Evaluation
MACE Military Acute Concussion Evaluation Patient Name: Service Member ID#: Unit: Date of Injury: Time of Injury: Examiner: Date of Evaluation: Time of Evaluation: CONCUSSION SCREENING Complete this section
More informationSociology 63993, Exam1 February 12, 2015 Richard Williams, University of Notre Dame,
Sociology 63993, Exam1 February 12, 2015 Richard Williams, University of Notre Dame, http://www3.nd.edu/~rwilliam/ I. True-False. (20 points) Indicate whether the following statements are true or false.
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationAdministrative Procedure
Durham Catholic District School Board The Board Title: Eyewash Stations and Safety Showers Procedure #: AP414-12 Administrative Area: Policy Reference: Human Resources and Administrative Services Emergency
More informationImputing Dose Levels for Adverse Events
Paper HO03 Imputing Dose Levels for Adverse Events John R Gerlach & Igor Kolodezh CSG Inc., Raleigh, NC USA ABSTRACT Besides the standard reporting of adverse events in clinical trials, there is a growing
More informationVersion No. 7 Date: July Please send comments or suggestions on this glossary to
Impact Evaluation Glossary Version No. 7 Date: July 2012 Please send comments or suggestions on this glossary to 3ie@3ieimpact.org. Recommended citation: 3ie (2012) 3ie impact evaluation glossary. International
More informationA COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY
A COMPARISON OF IMPUTATION METHODS FOR MISSING DATA IN A MULTI-CENTER RANDOMIZED CLINICAL TRIAL: THE IMPACT STUDY Lingqi Tang 1, Thomas R. Belin 2, and Juwon Song 2 1 Center for Health Services Research,
More informationWarfarin Help Documentation
Warfarin Help Documentation Table Of Contents Warfarin Management... 1 iii Warfarin Management Warfarin Management The Warfarin Management module is a powerful tool for monitoring INR results and advising
More informationChapter 11 Nonexperimental Quantitative Research Steps in Nonexperimental Research
Chapter 11 Nonexperimental Quantitative Research (Reminder: Don t forget to utilize the concept maps and study questions as you study this and the other chapters.) Nonexperimental research is needed because
More informationMeasuring impact. William Parienté UC Louvain J PAL Europe. povertyactionlab.org
Measuring impact William Parienté UC Louvain J PAL Europe povertyactionlab.org Course overview 1. What is evaluation? 2. Measuring impact 3. Why randomize? 4. How to randomize 5. Sampling and Sample Size
More information2.0 Synopsis. ABT-711 M Clinical Study Report R&D/06/054. (For National Authority Use Only) Referring to Part of Dossier: Volume: Page:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Depakote ER Name of Active Ingredient: Divalproex Sodium Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority
More informationGenerate Informative Clinical Laboratory Results Listing
PharmaSUG2011 - Paper PO02 Generate Informative Clinical Laboratory Results Listing Sai Ma, Everest Clinical Research Services Inc., Markham, Ontario Canada ABSTRACT Clinical laboratory results review
More informationSAFETY AND EFFICACY ASSESSMENTS
SAFETY AND EFFICACY ASSESSMENTS The observations and procedures described in (Primary Arthritis Assessments) and the Hip or Knee Pain on motion assessment described in (Secondary Arthritis Assessment)
More informationOperator tooling for the Touch-up Procedure
Operator tooling for the Touch-up Procedure Current State Current Process: After the printing process is complete part of the gold ink is not connected and the operator is required to touch-up this portion
More informationUN Handbook Ch. 7 'Managing sources of non-sampling error': recommendations on response rates
JOINT EU/OECD WORKSHOP ON RECENT DEVELOPMENTS IN BUSINESS AND CONSUMER SURVEYS Methodological session II: Task Force & UN Handbook on conduct of surveys response rates, weighting and accuracy UN Handbook
More informationPFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A3924 4 November 24 Final PFIZER INC. These results are supplied for informational purpose only. Prescribing decisions should be made based on the approved package insert.
More informationINTRODUCTION TO MACHINE LEARNING. Decision tree learning
INTRODUCTION TO MACHINE LEARNING Decision tree learning Task of classification Automatically assign class to observations with features Observation: vector of features, with a class Automatically assign
More informationKick It Old School - Creating Reports with the DATA _NULL_ Step
Kick It Old School - Creating Reports with the DATA _NULL_ Step Sai Ma, PharmaNet/i3, Toronto, Ontario Canada Suwen Li, Everest Clinical Research Services Inc., Markham, Ontario Canada Minlan Li, Everest
More informationSponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationClinical Trial Report Synopsis
This document has been do\vnloaded from \v ww.leo-pharma.com subject to the terms of use state on the website. It contains data and results regarding approved and non-approved uses, formulations or treatment
More informationRegression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, 2nd Ed.
Eric Vittinghoff, David V. Glidden, Stephen C. Shiboski, and Charles E. McCulloch Division of Biostatistics Department of Epidemiology and Biostatistics University of California, San Francisco Regression
More informationA (Constructive/Provocative) Critique of the ICH E9 Addendum
A (Constructive/Provocative) Critique of the ICH E9 Addendum Daniel Scharfstein Johns Hopkins University dscharf@jhu.edu April 18, 2018 1 / 28 Disclosures Regularly consult with pharmaceutical and device
More informationRapid Recovery Referral The Warm Handoff. Charles F. Barbera, MD, MBA, FACEP, FAAEM Chairman Department of Emergency Medicine
Rapid Recovery Referral The Warm Handoff Charles F. Barbera, MD, MBA, FACEP, FAAEM Chairman Department of Emergency Medicine Disclosures No relevant financial disclosures 2 Objectives Define rapid recovery
More informationIntro to SPSS. Using SPSS through WebFAS
Intro to SPSS Using SPSS through WebFAS http://www.yorku.ca/computing/students/labs/webfas/ Try it early (make sure it works from your computer) If you need help contact UIT Client Services Voice: 416-736-5800
More informationModeling of Hippocampal Behavior
Modeling of Hippocampal Behavior Diana Ponce-Morado, Venmathi Gunasekaran and Varsha Vijayan Abstract The hippocampus is identified as an important structure in the cerebral cortex of mammals for forming
More informationZITHROMAX (AZITHROMYCIN) SNDA H.3 CLINICAL TRIALS RELEVANT TO THE CLAIM STRUCTURE TABLE OF CONTENTS H.3.A. GENERAL APPROACH TO EVALUATION...
ZITHROMAX (AZITHROMYCIN) SNDA H.3 CLINICAL TRIALS RELEVANT TO THE CLAIM STRUCTURE TABLE OF CONTENTS H.3.A. GENERAL APPROACH TO EVALUATION...2 H.3.A.1 Efficacy (Pfizer IND Studies)...2 H.3.A.1.A Summary
More information